Literature DB >> 29950292

Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation.

Wenbin Xiao1, Mariko Yabe1, Michael Offin2, Pallavi Khattar1, Jeeyeon Baik1, Ryan J Daley2, Jeremy J Pappacena2, Mikhail Roshal1, Yanming Zhang1, Martin S Tallman2, Sheng F Cai2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29950292      PMCID： PMC6039660          DOI： 10.1182/bloodadvances.2018016675

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  8 in total

1.  Implications of NRAS mutations in AML: a study of 2502 patients.

Authors:  Ulrike Bacher; Torsten Haferlach; Claudia Schoch; Wolfgang Kern; Susanne Schnittger
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

2.  The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization.

Authors:  T Haferlach; M Winkemann; H Löffler; R Schoch; W Gassmann; C Fonatsch; C Schoch; M Poetsch; K Weber-Matthiesen; B Schlegelberger
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

3.  The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

Authors:  Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

4.  RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

Authors:  David T Bowen; Marion E Frew; Robert Hills; Rosemary E Gale; Keith Wheatley; Michael J Groves; Stephen E Langabeer; Panagiotis D Kottaridis; Anthony V Moorman; Alan K Burnett; David C Linch
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

5.  Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Authors:  Qing Li; Kevin M Haigis; Andrew McDaniel; Emily Harding-Theobald; Scott C Kogan; Keiko Akagi; Jasmine C Y Wong; Benjamin S Braun; Linda Wolff; Tyler Jacks; Kevin Shannon
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

6.  Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.

Authors:  Chezi Ganzel; Judith Manola; Dan Douer; Jacob M Rowe; Hugo F Fernandez; Elisabeth M Paietta; Mark R Litzow; Ju-Whei Lee; Selina M Luger; Hillard M Lazarus; Larry D Cripe; Peter H Wiernik; Martin S Tallman
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

7.  Abnormal chromosome 16 in clonogenic eosinophils from a case of acute myeloid leukemia (FAB,M2).

Authors:  P E Hollings; I Rosman; M E Beard; P H Fitzgerald
Journal:  Cancer Genet Cytogenet       Date:  1988-04

8.  Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.

Authors:  Andreas Neubauer; Kati Maharry; Krzysztof Mrózek; Christian Thiede; Guido Marcucci; Peter Paschka; Robert J Mayer; Richard A Larson; Edison T Liu; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.